CryoPort (NASDAQ:CYRX) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of CryoPort (NASDAQ:CYRX) from a hold rating to a sell rating in a research report sent to investors on Sunday.

A number of other research analysts have also recently commented on CYRX. Needham & Company LLC increased their target price on CryoPort from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Craig Hallum initiated coverage on CryoPort in a research note on Monday, March 30th. They set a “buy” rating and a $15.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CryoPort in a research note on Friday, March 27th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, CryoPort has an average rating of “Moderate Buy” and a consensus target price of $13.31.

CryoPort Price Performance

CYRX opened at $10.35 on Friday. The stock has a market cap of $519.57 million, a PE ratio of 7.84 and a beta of 1.75. CryoPort has a 52 week low of $5.31 and a 52 week high of $11.45. The business’s fifty day simple moving average is $8.92 and its 200 day simple moving average is $9.32.

CryoPort (NASDAQ:CYRX) last released its earnings results on Tuesday, March 3rd. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The firm had revenue of $45.45 million during the quarter, compared to the consensus estimate of $42.92 million. CryoPort had a net margin of 42.35% and a negative return on equity of 8.22%. As a group, equities analysts anticipate that CryoPort will post -0.73 earnings per share for the current year.

Insider Activity

In other news, insider Mark W. Sawicki sold 3,235 shares of the firm’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $8.00, for a total transaction of $25,880.00. Following the transaction, the insider directly owned 103,697 shares of the company’s stock, valued at approximately $829,576. This trade represents a 3.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Robert Stefanovich sold 38,700 shares of the firm’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $7.76, for a total value of $300,312.00. Following the transaction, the chief financial officer directly owned 255,701 shares in the company, valued at $1,984,239.76. This trade represents a 13.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 59,939 shares of company stock valued at $471,183. 10.10% of the stock is currently owned by insiders.

Institutional Trading of CryoPort

Large investors have recently modified their holdings of the business. SG Americas Securities LLC grew its stake in shares of CryoPort by 663.2% in the third quarter. SG Americas Securities LLC now owns 127,280 shares of the company’s stock worth $1,207,000 after purchasing an additional 110,602 shares during the last quarter. Mak Capital One LLC bought a new stake in shares of CryoPort in the third quarter worth about $7,756,000. Segall Bryant & Hamill LLC bought a new stake in shares of CryoPort in the third quarter worth about $652,000. Conestoga Capital Advisors LLC grew its stake in shares of CryoPort by 52.0% in the fourth quarter. Conestoga Capital Advisors LLC now owns 159,864 shares of the company’s stock worth $1,535,000 after purchasing an additional 54,675 shares during the last quarter. Finally, Harbor Capital Advisors Inc. bought a new stake in shares of CryoPort in the fourth quarter worth about $352,000. 92.90% of the stock is owned by institutional investors.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.